Toothpaste ingredient can combat malaria, finds robot scientist

Image
IANS London
Last Updated : Jan 18 2018 | 6:41 PM IST

An anti-bacterial and anti-fungal agent commonly found in toothpaste, soaps and detergents can be used as a drug against strains of malaria parasite that have grown resistant, a study led by an artificially-intelligent "robot scientist" has revealed.

The study aided by the robot scientist "Eve" discovered that the ingredient "triclosan" affects parasite growth by specifically inhibiting an enzyme of the malaria parasite, called "DHFR".

"DHFR" is the target of a well-established antimalarial drug, pyrimethamine. However, resistance to the drug among malaria parasites is common, particularly in Africa.

The researchers showed that "triclosan" was able to target and act on this enzyme, even in pyrimethamine-resistant parasites.

"The discovery by our robot "colleague" Eve that 'triclosan' is effective against malaria targets offers hope that we may be able to use it to develop a new drug," said lead author Elizabeth Bilsland, Assistant Professor at the University of Campinas in Brazil.

"We know it is a safe compound, and its ability to target two points in the malaria parasite's lifecycle means the parasite will find it difficult to evolve resistance," Bilsland added in a paper published in the journal Scientific Reports.

When used in toothpaste, "triclosan" prevents the build-up of plaque bacteria by inhibiting the action of an enzyme known as enoyl reductase (ENR), which is involved in the production of fatty acids in liver.

But, as the study showed that "triclosan" has the potential to inhibit both ENR and DHFR, it may be possible to target the parasite at both the liver stage and the later blood stage, the researchers said.

Malaria kills over half a million people each year, pre-dominantly in Africa and south-east Asia.

While a number of medicines are used to treat the disease, the malaria parasites are growing increasingly resistant to these drugs, raising the spectre of untreatable malaria in the future.

--IANS

rt/na/dg

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jan 18 2018 | 6:32 PM IST

Next Story